September 3, 2021
New Paper: Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP)
Abstract Animal models are important in preclinical psychopharmacology to study mechanisms and potential treatments for psychiatric disorders. A working group of 14 volunteers, comprising an international team of researchers from academia and industry, convened in 2021 to discuss how to improve the translational relevance and interpretation of findings from animal models that are used in […]
August 23, 2023
Psychiatry Consortium Wins Bionow Partnership and Collaboration Award
The Psychiatry Consortium was named winner of the Partnership and Collaboration Award the Bionow Awards 2022 (16 March 2023). Established in 2019, and managed by Medicines Discovery Catapult (MDC), the Psychiatry Consortium is a strategic collaboration of leading medical research charities and pharmaceutical companies. It focuses on identifying and validating novel drug targets to address […]
March 21, 2023
Medicine Discovery Catapult’s Psychiatry Consortium announces new international collaboration to tackle depression
The University of Trento and the University of Bologna are collaborating with global pharmaceutical companies including, Biogen Inc, Janssen Pharmaceutica NV and Merck Sharp and Dohme Corp. in a new Psychiatry Consortium project that will seek to define a new pharmacological approach to treat depression. Launching in February 2022, the project will see academic and industry partners combine efforts […]
December 14, 2021
Psychiatry medicines discovery champion wins prestigious industry award
Dr. Laura Ajram, Psychiatry Consortium Programme Manager at Medicines Discovery Catapult (MDC) has landed the prestigious ELRIG Early Career Impact Award 2021. The ELRIG (European Laboratory Research and Innovation Group) Early Career Professional Impact Award, recognises and celebrates the achievements of early-career professionals (ECP) who have made a clear, demonstrable impact on the wider scientific community. Dr Laura Ajram […]
October 1, 2021
A new initiative to revitalise drug discovery in psychiatric disease: the Psychiatry Consortium launches first call for proposals
Today (3rd October 2019) the Psychiatry Consortium announces its first call for projects that focus on the identification of novel drug targets to address the unmet therapeutic needs of people with mental health conditions. Applicants can submit project proposals to the consortium from the 7th of October 2019. The Psychiatry Consortium is a pioneering collaboration between […]
September 22, 2021
Psychiatry Consortium brings Charles River Laboratories and Evotec on board
World-leading drug discovery organisations Charles River Laboratories and Evotec join the Psychiatry Consortium as drug discovery and development partners.The two organisations bring invaluable expertise and capabilities to the Psychiatry Consortium, significantly enhancing the offering to the research community.The Psychiatry Consortium, managed by Medicines Discovery Catapult, brings together academia, industry, charity and government-funded organisations to develop and deliver a portfolio of innovative collaborative projects to identify […]
September 22, 2021
Global Expansion: Psychiatry Consortium Welcomes New International Partner
Shionogi & CO., LTD. (known as “Shionogi”), a leading global research-driven pharmaceutical company, has joined the Psychiatry Consortium – an international collaboration to accelerate drug discovery and development in this area of urgent, unmet medical need. The Psychiatry Consortium, managed by Medicines Discovery Catapult, is a strategic collaboration of leading medical research charities and eight pharmaceutical companies focusing […]
September 3, 2021
Accelerated and more efficient drug discovery in psychiatry – the impetus behind a year of upcoming activity between the Psychiatry Consortium and BNA
Psychiatric drug discovery must be a truly collaborative process if it is to be successful. To enable a more unified approach, we need a better handover between disciplines and a systematic and structured pathway to take an identified target through the drug discovery process.All too often industry and academia work exclusively, developing transformative work in […]
April 9, 2021
Investigating new treatment for schizophrenia as first Psychiatry Consortium funded project announced
A partnership between the University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia. This is the first project to be funded by the international Psychiatry Consortium, a £4 million collaboration between seven global pharmaceutical companies, and two leading research […]
January 21, 2021
Boost for Mental Health Medicines R&D as COMPASS Pathways Joins the Psychiatry Consortium
Global mental health care company, COMPASS Pathways has joined the Psychiatry Consortium, bringing additional expertise and insights to the group.A company dedicated to accelerating patient access to evidence-based innovation in mental health, COMPASS Pathways will further enhance the Consortium’s collective intelligence and reach.Managed by Medicines Discovery Catapult, the Psychiatry Consortium comprises prominent players across industry, charities and academia, […]
September 3, 2021
Target validation in psychiatry: addressing unmet therapeutic needs
Dr. Ekta Patel, Psychiatry Consortium Partnership Manager at Medicines Discovery Catapult (MDC), spoke to DDW’s Diana Spencer about how the guide can help researchers to create a target validation package and the need for new therapeutic targets in this underfunded specialty. Read the blog
December 16, 2022
Improving translational research along the psychiatric drug discovery pipeline
Dr. Laura Ajram, Psychiatry Consortium Programme Manager at Medicines Discovery Catapult (MDC), discusses her work on the inception and management of MDC’s Psychiatry Consortium, a pioneering collaboration between medical charities, pharma, and healthcare organizations focusing on novel drug discovery in mental health. In this interview with The Scientists Channel, Ajram, who won the prestigious 2021 […]
January 12, 2022
Meet Dr Laura Ajram from the Psychiatry Consortium
In November 2020, COMPASS Pathways joined the Psychiatry Consortium, an international collaboration to accelerate drug discovery and development in areas of urgent, unmet medical need. Here we speak to Laura Arjam, Psychiatry Consortium Programme Manager, about her role, the Consortium, and what inspired her to work in mental health.What is your role at the Psychiatry […]
September 17, 2021
Driving Advances in Drug Discovery for Mental Health Conditions
Dr. Ekta Patel, Psychiatry Consortium Partnership Manager at Medicines Discovery Catapult (MDC), discusses the importance of understanding and addressing the unmet therapeutic needs of individuals living with mental health conditions. Read the introductory piece
September 3, 2021
Meet the Psychiatry Consortium: Driving advances in drug discovery for mental health conditions
Dr. Ekta Patel, Psychiatry Consortium Partnership Manager at Medicines Discovery Catapult (MDC), talks about driving advances in our knowledge of disease biology to help unlock new treatment targets for mental health conditions. Read the blog
Delivering the next generation drug discovery pipeline; New approaches to target identification and target validation
A workshop co-hosted by the Psychiatry Consortium and the Psychiatric Genomics Consortium. Psychiatric drug discovery has the potential to be re-invigorated by recent advances in genomics. Increases in whole genome sequencing and larger genome-wide association studies (GWAS) have yielded an unprecedented trove of new knowledge about the genetic underpinnings of psychiatric diseases and, with it, […]
Innovative drug discovery consortium to address unmet therapeutic needs of people living with mental health conditions
In June 2019, Medicines Discovery Catapult, MQ: Transforming mental health and Alzheimer’s Research UK formed an innovative drug discovery consortium with industry, supported by Wellcome.The Psychiatry Consortium aims to identify and validate novel drug targets to address unmet therapeutic needs and psychiatric symptoms affecting people with mental health conditions and dementia.The Psychiatry Consortium is part of MDC’s […]
News
September 3, 2021
New Paper: Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP)
Abstract Animal models are important in preclinical psychopharmacology to study mechanisms and potential treatments for psychiatric disorders. A working group of 14 volunteers, comprising an international team of researchers from academia and industry, convened in 2021 to discuss how to improve the translational relevance and interpretation of findings from animal models that are used in […]
August 23, 2023
Psychiatry Consortium Wins Bionow Partnership and Collaboration Award
The Psychiatry Consortium was named winner of the Partnership and Collaboration Award the Bionow Awards 2022 (16 March 2023). Established in 2019, and managed by Medicines Discovery Catapult (MDC), the Psychiatry Consortium is a strategic collaboration of leading medical research charities and pharmaceutical companies. It focuses on identifying and validating novel drug targets to address […]
March 21, 2023
Medicine Discovery Catapult’s Psychiatry Consortium announces new international collaboration to tackle depression
The University of Trento and the University of Bologna are collaborating with global pharmaceutical companies including, Biogen Inc, Janssen Pharmaceutica NV and Merck Sharp and Dohme Corp. in a new Psychiatry Consortium project that will seek to define a new pharmacological approach to treat depression. Launching in February 2022, the project will see academic and industry partners combine efforts […]
December 14, 2021
Psychiatry medicines discovery champion wins prestigious industry award
Dr. Laura Ajram, Psychiatry Consortium Programme Manager at Medicines Discovery Catapult (MDC) has landed the prestigious ELRIG Early Career Impact Award 2021. The ELRIG (European Laboratory Research and Innovation Group) Early Career Professional Impact Award, recognises and celebrates the achievements of early-career professionals (ECP) who have made a clear, demonstrable impact on the wider scientific community. Dr Laura Ajram […]
October 1, 2021
A new initiative to revitalise drug discovery in psychiatric disease: the Psychiatry Consortium launches first call for proposals
Today (3rd October 2019) the Psychiatry Consortium announces its first call for projects that focus on the identification of novel drug targets to address the unmet therapeutic needs of people with mental health conditions. Applicants can submit project proposals to the consortium from the 7th of October 2019. The Psychiatry Consortium is a pioneering collaboration between […]
September 22, 2021
Psychiatry Consortium brings Charles River Laboratories and Evotec on board
World-leading drug discovery organisations Charles River Laboratories and Evotec join the Psychiatry Consortium as drug discovery and development partners.The two organisations bring invaluable expertise and capabilities to the Psychiatry Consortium, significantly enhancing the offering to the research community.The Psychiatry Consortium, managed by Medicines Discovery Catapult, brings together academia, industry, charity and government-funded organisations to develop and deliver a portfolio of innovative collaborative projects to identify […]
September 22, 2021
Global Expansion: Psychiatry Consortium Welcomes New International Partner
Shionogi & CO., LTD. (known as “Shionogi”), a leading global research-driven pharmaceutical company, has joined the Psychiatry Consortium – an international collaboration to accelerate drug discovery and development in this area of urgent, unmet medical need. The Psychiatry Consortium, managed by Medicines Discovery Catapult, is a strategic collaboration of leading medical research charities and eight pharmaceutical companies focusing […]
September 3, 2021
Accelerated and more efficient drug discovery in psychiatry – the impetus behind a year of upcoming activity between the Psychiatry Consortium and BNA
Psychiatric drug discovery must be a truly collaborative process if it is to be successful. To enable a more unified approach, we need a better handover between disciplines and a systematic and structured pathway to take an identified target through the drug discovery process.All too often industry and academia work exclusively, developing transformative work in […]
April 9, 2021
Investigating new treatment for schizophrenia as first Psychiatry Consortium funded project announced
A partnership between the University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia. This is the first project to be funded by the international Psychiatry Consortium, a £4 million collaboration between seven global pharmaceutical companies, and two leading research […]
January 21, 2021
Boost for Mental Health Medicines R&D as COMPASS Pathways Joins the Psychiatry Consortium
Global mental health care company, COMPASS Pathways has joined the Psychiatry Consortium, bringing additional expertise and insights to the group.A company dedicated to accelerating patient access to evidence-based innovation in mental health, COMPASS Pathways will further enhance the Consortium’s collective intelligence and reach.Managed by Medicines Discovery Catapult, the Psychiatry Consortium comprises prominent players across industry, charities and academia, […]
